BPMC Blueprint Medicines Corp: institutional ownership and insider trading
6 funds reported holding $40.9M of Blueprint Medicines Corp in their latest 13F filings; in Q2 2026 funds net sold $38.7K, with 0 new positions and 1 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market; over its last four quarters it reported revenue of $562M and net income of −$156M.
BPMC revenue and earnings
- Quarter ended Mar 31, 2025: revenue $149M, net income $496K, EPS 0.01
- Quarter ended Dec 31, 2024: revenue $146M, net income −$50.0M, EPS -0.78
- Quarter ended Sep 30, 2024: revenue $128M, net income −$56.3M, EPS -0.89
- Quarter ended Jun 30, 2024: revenue $138M, net income −$50.0M, EPS -0.80
Largest institutional holders of BPMC
- Nuveen Asset Management, LLC — $36.6M
- NBW CAPITAL LLC — $4.32M
- Lindbrook Capital, LLC — $27.4K
- First Horizon Advisors, Inc. — $2.69K
- Cassady Schiller Wealth Management, LLC — $698
- HUNTINGTON NATIONAL BANK — $129
Recent BPMC insider trades
- Jul 3, 2025: Carter Percy H. sold 1,051 shares ($135K)
- Jul 3, 2025: Rossi Christina sold 1,172 shares ($150K)
- Jun 3, 2025: Carter Percy H. sold 2,659 shares ($340K)
- May 27, 2025: Albers Jeffrey W. sold 5,000 shares ($506K)
5%+ owners
- BlackRock, Inc.: 8.0% (Schedule 13G/A, filed Apr 23, 2025)
- Pentwater Capital Management LP: 6.0% (Schedule 13G, filed Aug 14, 2025)